Skip to main content
Medical information Clinical review pending

Genetic Testing

XPA Gene Xeroderma Pigmentosum Group A Genetic Test

Genetic test for mutations in the XPA gene, associated with Xeroderma Pigmentosum (XP), a condition causing extreme sun sensitivity and increased skin cancer risk. Utilizes Next Generation Sequencing (NGS).

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
Results
Confirm with the laboratory before booking.
Preparation
A clinical history of the patient is recommended. A genetic counseling session to draw a pedigree chart of affected family members is also advised prior to testing.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the XPA Gene Xeroderma Pigmentosum Group A Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Family history of Xeroderma Pigmentosum (XP)
  • ✓Extreme sensitivity to sunlight
  • ✓Early onset of skin lesions or skin cancers
  • ✓Suspected genetic predisposition to XP
  • ✓Genetic counseling for families with XP
02

In plain language

What this test helps you understand

This test helps identify mutations in the XPA gene, which are associated with Xeroderma Pigmentosum (XP). Identifying these mutations can aid in the diagnosis of XP, assess risk, and inform management strategies, particularly regarding sun protection and cancer surveillance.
The XPA Gene Xeroderma Pigmentosum Group A NGS Genetic DNA Test is a specialized diagnostic tool used to examine the XPA gene. This gene is crucial for repairing DNA damage, particularly damage caused by ultraviolet (UV) light from the sun. This test is important for individuals with a family history of xeroderma pigmentosum (XP), a rare genetic disorder characterized by extreme sensitivity to sunlight and a significantly increased risk of developing skin cancers.

This genetic test employs advanced Next Generation Sequencing (NGS) technology to identify specific mutations within the XPA gene. Detecting these mutations helps healthcare providers assess an individual's risk of developing XP and related conditions. Understanding this risk is vital for implementing appropriate preventative measures and management strategies.

Discuss your results with a healthcare professional. They can provide personalized interpretation based on your medical history and the test findings, guiding further steps and recommendations.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history of the patient is recommended. A genetic counseling session to draw a pedigree chart of affected family members is also advised prior to testing.
SampleBlood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
MethodologyNext Generation Sequencing (NGS) is used to detect mutations in the XPA gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the XPA gene. It does not detect mutations in other genes associated with Xeroderma Pigmentosum or other genetic conditions. A negative result does not completely rule out XP if clinical suspicion is high.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

XP is a rare genetic disorder where the body's ability to repair DNA damage caused by UV light is impaired, leading to extreme sun sensitivity and a high risk of skin cancer.
Individuals with a family history of XP, those experiencing extreme sun sensitivity, or those developing skin lesions/cancers at a young age should consider this test.
The test involves analyzing a sample of your blood or DNA using Next Generation Sequencing (NGS) to look for mutations in the XPA gene.
Confirm with the laboratory before booking.
It is essential to discuss your results with a healthcare professional or genetic counselor for proper interpretation and guidance on next steps.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp